Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,117.50 25.98 0.84%
FTSE 100 6,581.37 39.76 0.61%
DAX 9,247.97 74.26 0.81%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,697.50 26.24 0.12%

ABCAM Plc ABC Total Voting Rights



  ABCAM Plc (ABC) - Total Voting Rights

RNS Number : 1549Q
ABCAM Plc
01 November 2012
 



For immediate release 1 November 2012

                                  ABCAM PLC

                          ("Abcam" or "the Company")

               Total Voting Rights - Voting Rights and Capital

In conformity with 5.6.1 of the Disclosure and Transparency Rules, the
Company notifies the market of the following: 

The Company's issued share capital consists of 198,396,519 Ordinary Shares
of 0.2p each with voting rights. The Company does not hold any shares in
Treasury.

The above figure of 198,396,519 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the Company under
the FSA's Disclosure and Transparency Rules.

Date of Notification: 1 November 2012

For further information please contact:

Abcam                                               + 44 (0) 1223 696 000
Jeff Iliffe, Chief Financial Officer

 
Numis Securities - Nominated Adviser & Joint Broker + 44 (0) 20 7260 1000
Michael Meade - Nominated Adviser
James Black - Corporate Broking

 
Peel Hunt LLP - Joint Broker                        + 44 (0) 20 7418 8900
Andy Crossley - Corporate Broking

 
Buchanan                                            + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles

 

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools.
These tools enable life scientists to analyse components of living cells at
the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK),
Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan),
Hangzhou and Hong Kong (both in China), allowing it to serve a global customer
base in over 130 countries. Abcam employs over 600 staff across its eight
operating companies.

Abcam now has an online catalogue of over 98,500 products sourced from over
400 suppliers. The catalogue includes a growing range of non-primary antibody
products such as secondaries, proteins, peptides, lysates, immunoassays and
other kits. Products are available for life science research and distributed
to academic and commercial users. A highly developed eCommerce platform, which
includes regional websites for the Chinese and Japanese markets, allows
customers to access up-to-date and detailed technical product data sheets at
the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol
ABC. The Company's vision is to be the world's leading life science tools
company.

 

                     This information is provided by RNS
           The company news service from the London Stock Exchange
 
END
 
 
TVRUGGAAGUPPGQG -0- Nov/01/2012 16:56 GMT
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement